# US 11,111,277 B2 · Influenza vaccines > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,111,277 B2 - Document ID: US11111277B2 - Status: Granted - Kind: B2 - Application number: 15/857,436 - Filed: 2017-12-28 - Published: 2018-08-16 - Granted: 2021-09-07 - Earliest claimed: 2016-12-28 - Assignees: InvVax, Inc.; The Regents of the University of California - Applicants: InvVax, Inc.; The Regents of the University of California - Inventors: Arthur Young; Ren Sun; Nicholas C. Wu - Web page: https://patentgrep.com/patent/US11111277B2 ## CPC - C07K 14/11: Orthomyxoviridae, e.g. influenza virus - A61K 39/12: Viral antigens - A61K 39/145: Orthomyxoviridae, e.g. influenza virus - A61P 31/16: for influenza or rhinoviruses - C07K 14/005: from viruses - C07K 14/075: Adenoviridae - C12N 15/86: Viral vectors - A61K 2039/5256: {expressing foreign proteins} - A61K 2039/5258: {Virus-like particles} - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/543: {intranasal} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers} - A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2} - A61K 2039/6018: {Lipids, e.g. in lipopeptides} - A61K 2039/70: {Multivalent vaccine} - C12N 2710/10343: viral genome or elements thereof as genetic vector - C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2760/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Provided herein are compositions related to vaccines, e.g., influenza vaccines, including, peptide based vaccines, nucleic acid based vaccines, recombinant virus based vaccines, antibody based vaccines, and virus based vaccines. Also provided herein are methods related to vaccines, e.g., influenza vaccines, including methods of identifying epitopes for the vaccines, producing, formulating, and administering the vaccines. ## Claims ### Claim 1 A polypeptide comprising influenza virus epitopes, wherein the polypeptide comprises the sequences of SEQ ID NOs: 2, 3, 8, 11, 12, 17, 21, 22, 24, 32, 33, 34, 40, 41, 43, 49, 51, 52, 58, 59, 61, 62, 70, 73, 74, 75, 76, 77, 78, 82, 84, 85, 86, 92, 93, and 94. ### Claim 2 A polypeptide comprising influenza virus epitopes, wherein the polypeptide comprises: a first sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 8; a second sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 11; a third sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 12; a fourth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 2; a fifth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 3; a sixth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 32; a seventh sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 24; an eighth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 17; a ninth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 29; and a tenth sequence comprising at least 75% sequence identity to the sequence of SEQ ID NO: 33. ### Claim 3 (depends on 2) The polypeptide of claim 2, wherein the first sequence and second sequence are directly linked. ### Claim 4 (depends on 2) The polypeptide of claim 2, wherein at least two of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth sequence are linked by a linker. ### Claim 5 (depends on 4) The polypeptide of claim 4, wherein the linker comprises the sequence RVKR (SEQ ID NO: 110). ### Claim 6 (depends on 2) The polypeptide of claim 2, comprising the sequence of SEQ ID NO: 106. ### Claim 7 A polypeptide comprising influenza virus epitopes, wherein the polypeptide comprises: at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 8; at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 11; at least 4 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 12; at least 2 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 2; at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 3; at least 4 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 32; at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 21; at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 24; at least 3 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 17; at least 5 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 29; and at least 8 sequences comprising at least 75% sequence identity to the sequence of SEQ ID NO: 33. ### Claim 8 (depends on 2) A polynucleotide encoding the polypeptide of claim 2. ### Claim 9 (depends on 8) A composition comprising the polynucleotide of claim 8. ### Claim 10 (depends on 8) A vector comprising the polynucleotide of claim 8. ### Claim 11 (depends on 10) A composition comprising the vector of claim 10. ### Claim 12 (depends on 11) A method comprising administering to a subject the composition of claim 11.